Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:2101 |
| Name | vulva squamous cell carcinoma |
| Definition | A vulva carcinoma and has_material_basis_in squamous cells and is located_in the epidermis of the vulvar tissue. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer vulva cancer vulva carcinoma vulva squamous cell carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| MLH1 negative | Pembrolizumab | vulva squamous cell carcinoma | sensitive | detail... |
| MSH6 negative | Pembrolizumab | vulva squamous cell carcinoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03212469 | Phase Ib/II | Durvalumab + Tremelimumab | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) | Completed | FRA | 0 |
| NCT03357757 | Phase II | Avelumab + Valproic acid | Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) | Completed | CAN | 0 |
| NCT03946358 | Phase II | Atezolizumab + UCPVax | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL) | Completed | FRA | 0 |
| NCT04357873 | Phase II | Pembrolizumab + Vorinostat | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) | Completed | FRA | 0 |
| NCT04430699 | Phase II | Cisplatin + Pembrolizumab | Cisplatin+Pembrolizumab+RT in Vulvar Cancer | Active, not recruiting | USA | 0 |
| NCT04708470 | Phase Ib/II | Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | Active, not recruiting | USA | 0 |
| NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Active, not recruiting | NZL | AUS | 0 |
| NCT05903833 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (PIERCE) | Recruiting | DEU | 0 |
| NCT06639191 | Phase I | 177Lu-AKIR001 | [177Lu]Lu-AKIR001 First-in-human Study (AKIR001) | Not yet recruiting | SWE | 0 |
| NCT07101848 | Phase II | Cemiplimab | A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER (BRAVA VULVAR) | Not yet recruiting | BRA | 0 |
| NCT07217171 | Phase I | EVOLVE104 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Recruiting | USA | 0 |